These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36250238)

  • 1. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
    Butler J; Usman MS; Anstrom KJ; Blaustein RO; Bonaca MP; Ezekowitz JA; Freitas C; Lam CSP; Lewis EF; Lindenfeld J; McMullan CJ; Mentz RJ; O'Connor C; Rosano GMC; Saldarriaga CI; Senni M; Udelson J; Voors AA; Zannad F
    Eur J Heart Fail; 2022 Nov; 24(11):2029-2036. PubMed ID: 36250238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
    Cordwin DJ; Berei TJ; Pogue KT
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):593-600. PubMed ID: 34487435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vericiguat for the treatment of heart failure with reduced ejection fraction.
    Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.
    Kassis-George H; Verlinden NJ; Fu S; Kanwar M
    Ther Clin Risk Manag; 2022; 18():315-322. PubMed ID: 35386181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure].
    Belenkov YN; Kozhevnikova MV
    Kardiologiia; 2023 May; 63(5):68-76. PubMed ID: 37307211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
    Pieske B; Butler J; Filippatos G; Lam C; Maggioni AP; Ponikowski P; Shah S; Solomon S; Kraigher-Krainer E; Samano ET; Scalise AV; Müller K; Roessig L; Gheorghiade M;
    Eur J Heart Fail; 2014 Sep; 16(9):1026-38. PubMed ID: 25056511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction.
    Tran BA; Serag-Bolos ES; Fernandez J; Miranda AC
    J Pharm Pract; 2023 Aug; 36(4):905-914. PubMed ID: 35356844
    [No Abstract]   [Full Text] [Related]  

  • 13. Vericiguat for Heart Failure with Reduced Ejection Fraction.
    Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
    Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF).
    Xia J; Hui N; Tian L; Liang C; Zhang J; Liu J; Wang J; Ren X; Xie X; Wang K
    Biomed Pharmacother; 2022 May; 149():112894. PubMed ID: 35367763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vericiguat: A New Hope for Heart Failure Patients.
    Chiles R; Al-Horani RA
    Cardiovasc Ther; 2022; 2022():1554875. PubMed ID: 36618548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure.
    Liang WL; Liang B
    Curr Cardiol Rep; 2023 Jun; 25(6):607-613. PubMed ID: 37079245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
    Trujillo ME; Ayalasomayajula S; Blaustein RO; Gheyas F
    Clin Transl Sci; 2023 Dec; 16(12):2458-2466. PubMed ID: 37997225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
    Emdin M; Aimo A; Castiglione V; Vergaro G; Georgiopoulos G; Saccaro LF; Lombardi CM; Passino C; Cerbai E; Metra M; Senni M
    J Am Coll Cardiol; 2020 Oct; 76(15):1795-1807. PubMed ID: 33032741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.